Core Viewpoint - The current market is considered expensive, with the Shiller CAPE ratio at 39.6, indicating a potential correction or bear market is likely approaching [1][2] Market Context - Historical data shows that corrections of 10% are common, with the S&P 500 experiencing an average annual correction of at least 10% since 1950, and a 20% correction occurring every three to five years on average [2] Defensive Investment Strategy - Defensive sectors such as healthcare, consumer staples, and utilities are expected to perform well during market corrections and bear markets [3] - Dividend stocks are highlighted as favorable investments during sideways and bear markets due to their income generation [3] Selected Stocks for Mini Portfolio - A mini portfolio of eight stocks, all classified as Dividend Kings (companies that have increased dividends for 50 consecutive years), is recommended for market drawdowns [4] - These stocks are positioned in defensive sectors and offer dividend yields above the S&P 500 index yield of 1.25% [4] Individual Stock Highlights - **Coca-Cola (KO)**: Dividend yield of 2.9%, increased dividends for 63 years, current price around $70.61, market cap $303 billion [5][6] - **Procter & Gamble (PG)**: Dividend yield of 2.86%, increased dividends for 69 years, current price around $147 [7] - **Johnson & Johnson (JNJ)**: Dividend yield of 2.7%, increased dividends for 62 years, current price around $186.57, market cap $450 billion [8][9] - **American States Water (AWR)**: Dividend yield of 2.54%, increased dividends for 71 years, current price around $74.84, market cap $3 billion [10][11] - **Northwest Natural Holding (NWN)**: Highest yield at 4.21%, increased dividends for 70 years, current price around $47 [12] - **Genuine Parts (GPC)**: Dividend yield of 3.3%, increased dividends for 69 years, current price around $127 [13] - **Marzetti Co. (MZTI)**: Dividend yield of 2.21%, increased dividends for 62 years, current price around $172 [13] - **Becton, Dickinson (BDX)**: Dividend yield of 2.35%, increased dividends for 53 years, current price around $178 [14] Total Investment Overview - The total cost to purchase one share of each of these eight stocks is approximately $1,000, creating a defensive income-generating portfolio [15]

Core Insights - Project C.U.R.E. collaborates with Microsoft to enhance global healthcare access and save lives through innovative technology solutions [1][3][6] - Over 4.5 billion people globally lack access to essential health services, with 80% of individuals in low-income countries facing similar challenges [1][2] - Project C.U.R.E. has evolved from a garage startup to a major nonprofit, delivering medical supplies to over 135 countries with the help of 35,000 volunteers [2][7] Technology Integration - The partnership with Microsoft utilizes Dynamics 365, Power Platform, Power BI, and Microsoft Teams to streamline operations and create a data-driven system [3][5] - Automation through Power Platform has reduced manual work from 80% to 15%, improving efficiency in various operational areas [4] - Real-time tracking of financial, inventory, and shipping data enhances accountability and transparency for donors and partners [5] Organizational Impact - The integration of Microsoft technology has led to increased team creativity and energy, positively impacting donor engagement [6] - Project C.U.R.E. aims to leverage technology and compassion to strengthen healthcare systems globally [6]

Core Insights - Henry Schein Inc. reported third-quarter adjusted earnings of $1.38, a 13.1% increase year over year, surpassing the consensus estimate of $1.28 [1] - The company's sales totaled $3.34 billion, exceeding the consensus estimate of $3.28 billion, with a net sales increase of 5.2% compared to the third quarter of 2024 [2] Financial Performance - Global Distribution and Value-Added Services sales reached $2.84 billion, up 4.8% [3] - Global Specialty Products sales were $369 million, reflecting a 5.9% increase driven by strong growth in dental implant and endodontics sales [3] - Global Technology sales increased by 9.7% to $173 million, with a 9.0% increase in constant currencies, attributed to the adoption of cloud-based software and new revenue cycle management solutions [4] Share Repurchase and Strategic Moves - During the third quarter, the company repurchased approximately 3.3 million shares at an average price of $68.62 per share, totaling $229 million [5] - Henry Schein has $980 million authorized for future stock repurchases [5] - An amendment to the Strategic Partnership Agreement allows KKR & Co to increase its ownership in Henry Schein stock up to 19.9% through open market purchases [6] Guidance and Future Outlook - The company raised its fiscal 2025 adjusted earnings guidance to a range of $4.88 to $4.96 per share, compared to the previous guidance of $4.80 to $4.94 [7] - Sales guidance was increased from $12.425 billion to $13.180 billion, reflecting a projected sales growth of approximately 3% to 4% over 2024 [7] - Adjusted EBITDA growth for 2025 is expected to increase in the mid-single digits compared to 2024, remaining unchanged [8] Stock Performance - Henry Schein shares rose by 9.48% to $70.77 at the time of publication [8]

Core Insights - InfuSystem reported record net revenues of $36.5 million for Q3 2025, representing a 3% growth from the prior year [1][4][6] - Net income increased by 25% to $2.3 million, with adjusted EBITDA rising 6% to $8.3 million [1][4][15] - The company reaffirmed its full-year 2025 guidance, expecting net revenue growth of 6% to 8% and an adjusted EBITDA margin of 20% or higher [1][18] Financial Performance - Net revenues for Q3 2025 were $36.5 million, up $1.2 million or 3.3% from $35.3 million in Q3 2024 [4][6] - Patient Services segment net revenue was $22.4 million, an increase of 8% year-over-year, while Device Solutions segment net revenue decreased by 3% to $14.1 million [4][7][8] - Gross profit for Q3 2025 was $20.8 million, a 9% increase from the prior year, with a gross margin of 57.1% [4][9] Segment Analysis - Wound care revenue increased by nearly $1.0 million, or 115%, year-over-year, attributed to a new supplier relationship for Pneumatic Compression Devices [3][7] - Oncology revenue saw a record quarter, benefiting from a new contract with a large hospital system [3][7] - Device Solutions segment experienced a decrease in medical equipment sales by $0.8 million, or 33%, but a 5.2% increase in biomedical services revenue [8][11] Cost Management - Selling and marketing expenses decreased by 14.1% to $2.4 million, reflecting a reduction in sales team members and improved cost coverage [12] - General and administrative expenses increased by 12.9% to $14.4 million, driven by IT upgrades and personnel costs related to revenue growth [13] Cash Flow and Liquidity - Year-to-date net operating cash flow was $17.3 million, up 38% compared to the prior year [1][16] - As of September 30, 2025, the company had liquidity of $54.6 million, consisting of $53.6 million in available borrowing capacity and $1.0 million in cash [17] Future Outlook - The company anticipates continued growth in its core business areas and plans to enhance service coverage and pricing through a multi-year extension with a national insurance payer [3][5] - Management is focused on profitable growth and improving operational processes to lower costs [3]

- Emil Lendof/WSJ Software company Navan plans to make its stock-market debut Thursday despite a government shutdown that has stalled other new listings. Navan priced its offering at $25 a share, valuing Navan at roughly $6.2 billion, and raised around $923 million for the company and selling shareholders. It is the biggest company so far to stage an initial public offering using a workaround provided by the Securities and Exchange Commission. Most Read from The Wall Street Journal The IPO market had b ...

Core Insights - Medline has filed for an initial public offering (IPO) in the U.S., aiming to raise $5 billion at a valuation of $50 billion, following a 10% sales growth to $13.5 billion [9] - The company differentiates itself through in-house distribution capabilities, allowing direct access to end-customer relationships [4] - Medline's prime vendor agreements, worth approximately $8 billion annually, are positioned as superior to competitors, with potential for an additional $1 billion in profits from converting clients to its own products [5] Company Overview - Founded in 1966, Medline offers around 335,000 products from 33 manufacturing facilities and 69 distribution centers, including surgical kits, gloves, and other medical-surgical products [3] - The company has seen net sales grow from roughly $10 billion in 2017 to $20 billion in 2021, with consistent revenue increases each year since [3] Growth Strategy - Medline plans to utilize IPO proceeds for general corporate purposes and is pursuing a global M&A strategy, having acquired Ecolab's global surgical solutions business for $905 million and Sinclair Dental for $195 million [8] - The company aims to expand into the $200 billion international market, with the U.S. currently accounting for 93% of its sales in 2024 [8] Regulatory Challenges - Medline faced a FDA warning letter and recall related to its brand products, particularly plastic syringes made in China, which impacted its sourcing capabilities [6] - The company also dealt with operational halts due to new state standards for ethylene oxide emissions, leading to litigation against insurers over denied coverage for settlement payments [7]

Company Overview - CYIOS Corporation LLC is a Nevada-registered holding company focused on acquisitions, modernization, and technology integration in the healthcare and medical supply sectors [1][5] - The company is actively expanding its presence in the U.S. medical distribution sector through its subsidiary Noir Medical Supplies, emphasizing operational excellence and sustainable profitability [5] Strategic Initiatives - CYIOS has engaged Atlanta Capital Partners, LLC to lead a renewed investor relations strategy aimed at enhancing visibility and communication within the investment community [1][4] - The current strategic plan includes reducing legacy debt, advancing targeted healthcare acquisitions, and scaling the AI-powered SaaS platform, CyioIQ [3] - The company aims to qualify for OTCQB and Nasdaq listings supported by a strengthened balance sheet [3] Growth and Transformation - The partnership with Atlanta Capital Partners is expected to elevate CYIOS's profile among investors seeking transformation-stage opportunities in high-demand sectors like healthcare technology [4] - Key initiatives under this partnership include expanded outreach to various investor types, consistent corporate updates, increased financial media exposure, and strategic event participation [4]

Company Overview - Henry Schein, Inc. is the world's largest provider of health care solutions to office-based dental and medical practitioners, offering over 300 valued solutions to more than 1 million customers globally [2][4] - The company operates through a centralized and automated distribution network, providing a selection of more than 300,000 branded products and corporate brand products [3] - Henry Schein is a FORTUNE 500 Company and a member of the S&P 500 index, with operations or affiliates in 33 countries and territories [4] Financial Performance - The company's sales reached $12.7 billion in 2024, growing at a compound annual rate of approximately 11.2 percent since becoming a public company in 1995 [4] Upcoming Events - Henry Schein will participate in investor conferences in November, including the Stifel's Healthcare Conference on November 12, 2025, and the Jefferies Healthcare Conference on November 18, 2025 [6] - The company will also webcast its third quarter 2025 financial results on November 4, 2025, at 8:00 A.M. Eastern time [9]

Core Insights - CYIOS Corporation announced the resignation of David Lewis, who returned 16,560 Series D Preferred Shares and canceled all salary and loan obligations, strengthening the company's balance sheet and simplifying its capital structure [1] - The company is completing PCAOB-audited financial statements for the past two years, with 2024 fully completed, enhancing transparency and compliance [2] - CYIOS is focusing on increasing working capital through strategic investments to pay down Noir Medical Supplies' debt obligations, expected to be completed by mid-2026 [2] - The company is engaging AI and SaaS advisors to develop CyioIQ, an AI-driven medical platform aimed at improving operational efficiency and profitability [3] - CYIOS Corporation operates across multiple industries, including medical supplies, technology, and fintech, with a focus on sustainable profitability through its subsidiary Noir Medical Supplies [4]

Market Outlook - Top Glove 预计在 2026 财年扩大美国销售额 [1] - 手套制造商面临来自中国竞争对手日益激烈的竞争 [1]